NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

In the past, studies in type-2 diabetes patients have linked Ozempic to the condition called non-arteritic anterior ischemic ...

This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran ...

A recent report suggested that more American teenagers now use the weight-loss drug Wegovy.However, experts stated that its ...

Dana Simmons wants you to know that if you are hungry, it is not your fault. In her recently released book, “On Hunger: ...

Also: A Medicare crisis and doctors’ concerns with Kennedy’s new coronavirus vaccine policy.

The European Medicines Agency’s (EMA) safety committee, PRAC, said Friday that it has concluded that Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), a rare eye condition that can lead to ...

Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye ...

A GROWING number of slimmers are trying to squeeze extra jabs out of empty Mounjaro pens in a risky bid to cut costs. The ...

A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

Omada Health is making its public-market debut, propelled by Americans’ renewed focus on how weight affects physical health.